Title: FDA MedWatch - Tracleer (Bosentan): Recommended Dosage Adjustment and Monitoring Guidelines to Avoid Hepatotoxicity
|
|
To print: Select File and then Print from your browser's menu Title: FDA MedWatch - Tracleer (Bosentan): Recommended Dosage Adjustment and Monitoring Guidelines to Avoid Hepatotoxicity |
|
"FDA MedWatch - Tracleer (Bosentan): Recommended Dosage Adjustment and Monitoring Guidelines to Avoid Hepatotoxicity" BETHESDA, M.D. -- March 2, 2006 -- Actelion and FDA notified healthcare professionals of changes to the Tracleer (bosentan) prescribing information based on cases of hepatotoxity reported. Tracleer is indicated for the treatment of pulmonary arterial hypertension. The notification underscored the need to continue monthly liver function monitoring for the duration of Tracleer treatment and the need to adhere to the recommended dosage adjustment and monitoring guidelines described in the product labeling. Read the complete MedWatch 2006 Safety summary, including links to the Dear Healthcare Professional letter, revised prescribing information and medication guide at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#Tracleer SOURCE: FDA Safety Information and Adverse Event Reporting Program |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |